What’s New

News

Jan 8, 2024

Alimentiv Announces Pierre Gaudreault as New Chief Executive Officer

London, Ontario, Canada, January 8, 2024 – Alimentiv Inc. (“Alimentiv”) is pleased to announce the appointment of Pierre Gaudreault as its Chief Executive Officer, effective January 2024. Th…

News

Nov 8, 2023

Alimentiv, AcelaBio, and PharmaNest Unite To Revolutionize Precision Medicine and AI Digital Pathology For NASH/MASH Clinical Trials.

LONDON, ON, November 8, 2023 – Alimentiv Inc., AcelaBio Inc., and PharmaNest Inc. are pleased to announce their collaborative effort aimed at revolutionizing precision medicine and artificial in…

Publication

May 29, 2023

Systematic review and meta-analysis of randomised controlled trials: Medical therapies for the treatment and prevention of pouchitis

Christopher Ma, Rocio Sedano, Vipul Jairath.

Publication

May 1, 2023

Advanced Combination Treatment With Biologic Agents and Novel Small Molecule Drugs for Inflammatory Bowel Disease

Brian G Feagan, Christopher Ma, Vipul Jairath.

Publication

Apr 24, 2023

Real-World multicentre observational study with Pop-PK modelling to evaluate the exposure-response relationship of vedolizumab in IBD

Brian Feagan, Niels Vande Casteele.

Publication

Apr 17, 2023

ATRC Review: IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

Alimentiv Translational Research Consortium (ATRC), Niels Vande Casteele.

Publication

Apr 1, 2023

Endoscopic and Histological Placebo Rates in Crohn’s Disease Clinical Trials: A Systematic Review and Meta-analysis

Brian G Feagan, Christopher Ma, Vipul Jairath.

News

Mar 20, 2023

Celebrating our Women: Part Two

Continuing with our celebration during Women’s History Month and for International Women’s day, we are proud to profile two more of the incredible women that work at Alimentiv. Today, we a…